Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Operating Expenses (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Operating Expenses readings, the most recent being $19.8 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 46.64% to $19.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.0 million, a 5.84% increase, with the full-year FY2025 number at $73.0 million, up 5.85% from a year prior.
  • Operating Expenses hit $19.8 million in Q4 2025 for Avalo Therapeutics, up from $19.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $32.8 million in Q1 2024 to a low of $4.0 million in Q3 2023.
  • Median Operating Expenses over the past 5 years was $14.1 million (2024), compared with a mean of $15.7 million.
  • Biggest five-year swings in Operating Expenses: plummeted 63.28% in 2023 and later skyrocketed 253.59% in 2024.
  • Avalo Therapeutics' Operating Expenses stood at $18.2 million in 2021, then crashed by 46.37% to $9.8 million in 2022, then fell by 15.61% to $8.2 million in 2023, then skyrocketed by 64.09% to $13.5 million in 2024, then soared by 46.64% to $19.8 million in 2025.
  • The last three reported values for Operating Expenses were $19.8 million (Q4 2025), $19.2 million (Q3 2025), and $19.3 million (Q2 2025) per Business Quant data.